Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13476921 | 1.00 | LMNA (0.55) | LMNATSHRCHRM1AKR1A1CHRM3 | |
| SCHEMBL16280842 | 0.89 | — | — | |
| SCHEMBL30506692 | 0.89 | — | — | |
| SCHEMBL13894726 | 0.89 | — | — | |
| SCHEMBL30506721 | 0.89 | — | — | |
| SCHEMBL107904 | 0.89 | — | — | |
| SCHEMBL30506690 | 0.89 | — | — | |
| SCHEMBL30506689 | 0.89 | — | — | |
| SCHEMBL4819539 | 0.87 | LMNA (0.52) | LMNATSHRCHRM1AKR1A1CHRM3 | |
| SCHEMBL438490 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250040541-A1 | AN ANTIMICROBIAL LIQUID COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2025-02-06 | — | — | US | claimed |
| EP-4451875-A1 | AN ANTIMICROBIAL LIQUID COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP Investments LLC (US) | 2024-10-30 | — | — | EP | claimed |
| WO-2023122003-A1 | AN ANTIMICROBIAL LIQUID COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2023-06-29 | — | — | WO | claimed |
| US-20230147032-A1 | PROCESS FOR PRODUCING POLYMER CAPACITORS FOR HIGH RELIABILITY APPLICATIONS | HERAEUS EPURIO GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| US-20220081635-A1 | SYNTHETIC ESTERS DERIVED FROM HIGH STABILITY OLEIC ACID | QUAKER CHEMICAL CORPORATION (US) | 2022-03-17 | — | — | US | claimed |
| US-11155761-B2 | Synthetic esters derived from high stability oleic acid | QUAKER CHEMICAL CORPORATION (US) | 2021-10-26 | — | — | US | claimed |
| WO-2021198214-A2 | PROCESS FOR PRODUCING POLYMER CAPACITORS FOR HIGH RELIABILITY APPLICATIONS | Heraeus Deutschland GmbH & Co. KG (DE) | 2021-10-07 | — | — | WO | claimed |
| EP-3889980-A1 | PROCESS FOR PRODUCING POLYMER CAPACITORS FOR HIGH RELIABILITY APPLICATIONS | Heraeus Deutschland GmbH & Co KG (DE) | 2021-10-06 | — | — | EP | claimed |
| EP-2721093-B1 | PROCESS OF MAKING BETA-HYDROXYAMINO COMPOUNDS | PROCTER & GAMBLE (US) | 2019-10-02 | — | — | EP | claimed |
| US-20160040029-A1 | PHOTO-RESPONSIVE HYDROPHILIC COATING | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2016-02-11 | — | — | US | claimed |
| EP-1827433-A1 | A COMPOSITION COMPRISING AT LEAST 3 DIFFERENT DIOLS | Ambria Dermatology AB (SE) | 2007-09-05 | — | — | EP | claimed |
| WO-2007063065-A1 | USE OF A COMPOSITION COMPRISING PENTANE-1, 5-DIOL AS DEODORANT | AMBRIA DERMATOLOGY AB (SE) | 2007-06-07 | — | — | WO | claimed |
| WO-2006057616-A1 | A COMPOSITION COMPRISING AT LEAST 3 DIFFERENT DIOLS | AMBRIA DERMATOLOGY AB (SE) | 2006-06-01 | — | — | WO | claimed |
| US-6899753-B2 | Highly bleed-alleviating ink composition | BENQ CORPORATION (TW) | 2005-05-31 | — | — | US | claimed |
| US-6642170-B1 | Metals selected from tantalum, vanadium, niobium, chromium, molybdenum or tungsten on catalyst supports such as zeolites, oxides of silicon, aluminum, titanium, titanium, niobium or tantalum, used for etherification of alcohols-2+ | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2003-11-04 | — | — | US | claimed |
| US-20030037700-A1 | Highly bleed-alleviating ink composition | MIND FUSION, LLC | 2003-02-27 | — | — | US | claimed |
| EP-1109623-A1 | NOVEL SOLID OXIDATION CATALYSTS, IN PARTICULAR FOR EPOXIDATION OF PROCHIRAL COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000003802-A1 | NOVEL SOLID OXIDATION CATALYSTS, IN PARTICULAR FOR EPOXIDATION OF PROCHIRAL COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2000-01-27 | — | — | WO | claimed |
| EP-0471498-B1 | Optical resolution method | KANKYO KAGAKU CENTER (JP) | 1997-12-17 | — | — | EP | claimed |
| US-5395962-A | Optical resolution method | KANKYO KAGAKU CENTER CO., LTD. (JP) | 1995-03-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250040541-A1 | AN ANTIMICROBIAL LIQUID COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | RASGRP3, RSU1, RPP30 | LMNA 2815/4885TSHR 4641/4885CHRM1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.